Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
MorphoSys AG
MorphoSys AG
Activities:
Ingredients
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Research & Development
MorphoSys and Immatics Biotechnologies sign immuno-oncology agreement
To develop antibody based therapies against multiple cancers
Research & Development
Merck Serono and MorphoSys agree immuno-oncology collaboration
MorphoSys\' Ylanthia antibody technology will be used to identify antibodies to fight tumours
Research & Development
MorphoSys and Heptares to develop antibody therapeutics targeting GPCRs
MorphoSys will apply Ylanthia library to develop products against StaRs from Heptares
Research & Development
MorphoSys expands 10-year antibody alliance with Novartis
Long-standing agreement will benefit from technologies not available in 2007
Ingredients
MorphoSys makes two management appointments
Charlotte Lohmann and Martin Clark join the German firm
Ingredients
MorphoSys unveils new antibody technology
Ylanthia will show higher success rates and shorter timelines in antibody drug development
Manufacturing
Boehringer signs manufacturing agreement with MorphoSys
Covers process development and manufacturing of clinical material for MOR208 antibody
Subscribe now